GCP
ACIU icon

GSA Capital Partners’s AC Immune ACIU Stock Holding History

GSA Capital Partners’s Portfolio ACIU Stock Details ACIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,530
Closed -$32K – 1701
2026
Q1 		$32K Buy
+11,530
New +$35.8K ﹤0.01% 1626
2022
Q1 		– Sell
-73,046
Closed -$362K – 1362
2021
Q4 		$362K Buy
+73,046
New +$425K 0.05% 807
2020
Q2 		– Sell
-16,800
Closed -$116K – 580
2020
Q1 		$116K Sell
16,800
-15,300
-48% -$120K 0.03% 875
2019
Q4 		$273K Buy
32,100
+3,500
+12% +$23.3K 0.03% 1086
2019
Q3 		$142K Buy
+28,600
New +$153K 0.02% 1234
2018
Q4 		– Sell
-13,801
Closed -$110K – 1301
2018
Q3 		$110K Buy
+13,801
New +$139K 0.01% 1548
2017
Q2 		– Sell
-50,697
Closed -$525K – 1639
2017
Q1 		$525K Buy
50,697
+15,464
+44% +$190K 0.03% 1067
2016
Q4 		$457K Buy
+35,233
New +$488K 0.03% 1047

Other funds holding ACIU

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

GSA Capital Partners's ACIU Position: Q2 2026 in Review

GSA Capital Partners sold out of AC Immune (ACIU) in Q2 2026, closing a stake of 11,530 shares — an estimated $32K sold.

GSA Capital Partners first reported a position in ACIU in Q4 2016 and held it in 8 quarters. The position peaked at $525K in Q1 2017. 43 funds tracked by Wall St. Rank hold ACIU as of Q2 2026.

  • GSA Capital Partners reported no remaining AC Immune position as of Q2 2026 after selling out during the quarter.
  • GSA Capital Partners sold 11,530 AC Immune shares in Q2 2026, an estimated $32K.
  • GSA Capital Partners first reported a position in AC Immune in Q4 2016 and held it in 8 quarters.
  • GSA Capital Partners's AC Immune position peaked at $525K in Q1 2017.
  • 43 funds tracked by Wall St. Rank held AC Immune as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.